Ivabradine Kern Pharma 7.5 mg tablets EFG

Spain
Brand name Ivabradine Kern Pharma 7.5 mg tablets EFG
Form tablets
Active substance / Dosage
Prescription type Prescription Only Medicine
Registration number 81284
Manufacturer Kern Pharma S.L.
Ivabradine Kern Pharma 7.5 mg tablets EFG tablets

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Ivabradine Kern Pharma 7.5 mg tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
  • If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents:

  1. What Ivabradine Kern Pharma tablets are and what they are used for
  2. What you need to know before taking Ivabradine Kern Pharma tablets
  3. How to take Ivabradine Kern Pharma tablets
  4. Possible adverse effects
  5. How to store Ivabradine Kern Pharma tablets
  6. Contents of the pack and other information

1. What Ivabradina Kern Pharma tablets are and what they are used for

Ivabradine is a heart medication used to treat:

  • Symptomatic stable angina (which causes chest pain) in adult patients whose heart rate is greater than or equal to 70 beats per minute. It is used in adult patients who cannot tolerate or cannot take heart medications known as beta-blockers. It is also used in combination with beta-blockers in adult patients whose condition is not fully controlled with a beta-blocker alone.
  • Chronic heart failure in adult patients whose heart rate is greater than or equal to 75 beats per minute. It is used in combination with standard therapy, including treatment with beta-blockers, or when beta-blockers are contraindicated or not tolerated.

About stable angina (commonly known as “angina”):

Stable angina is a heart condition that occurs when the heart does not receive enough oxygen. It typically appears between the ages of 40 and 50. The most common symptom of angina is chest pain or discomfort. Angina is more likely to occur when the heart beats faster, such as during exercise, emotional stress, exposure to cold, or after eating. This increase in heart rate can trigger chest pain in people with angina.

About chronic heart failure:

Chronic heart failure is a heart condition that occurs when your heart cannot pump enough blood to the rest of the body. The most common symptoms of heart failure are shortness of breath, fatigue, tiredness, and swelling of the ankles.

How does Ivabradine work?

Ivabradine works primarily by reducing the heart rate by a few beats per minute. This decreases the heart's oxygen demand, particularly in situations where an angina attack is more likely to occur. Thus, Ivabradine tablets help control and reduce the number of angina attacks.

Additionally, since elevated heart rate negatively affects heart function and vital prognosis in patients with chronic heart failure, the specific heart rate-lowering action of Ivabradine helps improve heart function and vital prognosis in these patients.

2. What you need to know before taking Ivabradina Kern Pharma tablets

Do not take Ivabradina tablets

  • if you are allergic to ivabradine or to any of the other ingredients of this medicine (listed in section 6);
  • if your resting heart rate before treatment is too slow (below 70 beats per minute);
  • if you are suffering from cardiogenic shock (a heart condition treated in hospital);
  • if you have a heart rhythm disorder;
  • if you are having a heart attack;
  • if you have very low blood pressure;
  • if you have unstable angina (a severe type of angina in which chest pain occurs frequently, with or without exertion);
  • if you have heart failure that has recently worsened;
  • if your heart rate is solely determined by your pacemaker;
  • if you have severe liver problems;
  • if you are taking medicines for fungal infections (such as ketoconazole, itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin, or oral erythromycin), medicines for HIV infection (such as nelfinavir, ritonavir), or nefazodone (a medicine for depression), or diltiazem, verapamil (used for high blood pressure or angina pectoris);
  • if you are a woman of childbearing potential and are not using reliable contraceptive methods;
  • if you are pregnant or trying to become pregnant;
  • if you are breastfeeding.

Warnings and precautions

Talk to your doctor or pharmacist before taking Ivabradina tablets:

  • if you have heart rhythm disorders (such as irregular heartbeat, palpitations, increased chest pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality on the electrocardiogram (ECG) called "Long QT syndrome";
  • if you experience symptoms such as fatigue, dizziness, or difficulty breathing (this may mean your heart is beating too slowly);
  • if you develop symptoms of atrial fibrillation (unusually high resting pulse (over 110 beats per minute) or irregular pulse, without apparent reason, making it difficult to measure);
  • if you have recently had a stroke (cerebral attack);
  • if you have mild to moderate low blood pressure;
  • if you have uncontrolled blood pressure, especially after a change in your antihypertensive treatment;
  • if you have severe heart failure or heart failure with an ECG abnormality called "bundle branch block";
  • if you have chronic retinal eye disease;
  • if you have moderate liver problems;
  • if you have severe kidney problems.

If you have any of these conditions, consult your doctor immediately before or during treatment with Ivabradina tablets.

Children

Ivabradina tablets are not intended for use in children and adolescents under 18 years of age.

Taking Ivabradina tablets with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Make sure to inform your doctor if you are taking any of the following medicines, as a dose adjustment of Ivabradina tablets or monitoring may be necessary:

  • fluconazole (an antifungal medicine);
  • rifampicin (an antibiotic);
  • barbiturates (for sleep disorders or epilepsy);
  • phenytoin (for epilepsy);
  • Hypericum perforatum or St. John's wort (herbal remedy for depression);
  • Medicines that prolong the QT interval used to treat heart rhythm disorders or other conditions:
    • quinidine, disopyramide, ibutilide, sotalol, amiodarone (for treating heart rhythm disorders);
    • bepridil (for treating angina pectoris);
    • certain types of medicines for treating anxiety, schizophrenia, or other psychoses (such as pimozide, ziprasidone, sertindole);
    • antimalarial medicines (such as mefloquine or halofantrine);
    • intravenous erythromycin (an antibiotic);
    • pentamidine (an antiparasitic medicine);
    • cisapride (for gastroesophageal reflux).
  • Certain types of diuretics that may cause a reduction in blood potassium levels, such as furosemide, hydrochlorothiazide, indapamide (used to treat edema, high blood pressure).

Taking Ivabradina tablets with food and drink

Avoid grapefruit juice during treatment with Ivabradina tablets.

Pregnancy and breastfeeding

Do not take Ivabradina tablets if you are pregnant or intend to become pregnant (see "Do not take Ivabradina tablets").

If you are pregnant and have taken Ivabradina tablets, consult your doctor.

Do not take Ivabradina tablets if you are of childbearing potential unless you are using reliable contraceptive methods (see "Do not take Ivabradina tablets").

Do not take Ivabradina tablets if you are breastfeeding (see "Do not take Ivabradina tablets"). Talk to your doctor if you are breastfeeding or plan to start breastfeeding, as breastfeeding must be discontinued if you are taking Ivabradina tablets.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Driving and using machines

Ivabradina tablets may cause transient luminous phenomena (a brief sensation of brightness in the visual field, see "Possible side effects"). If this occurs, take care when driving or operating machinery in situations where sudden changes in light intensity may occur, especially when driving at night.

Ivabradina Kern Pharma contains lactose and glucose

This medicine contains lactose. If your doctor has informed you that you have an intolerance to certain sugars, consult him before taking this medicine.

This medicine contains glucose (from maltodextrin). If your doctor has informed you that you have an intolerance to certain sugars, consult him before taking this medicine.

3. How to take Ivabradina Kern Pharma tablets

Follow exactly the instructions for use of this medicine provided by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Ivabradina tablets should be taken with breakfast and dinner.

If you are being treated for stable angina

The starting dose should not exceed one 5 mg Ivabradina tablet twice daily. If you still have angina symptoms and have tolerated the 5 mg twice daily dose well, the dose may be increased. The maintenance dose should not exceed 7.5 mg twice daily. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g. if you are an elderly patient), your doctor may prescribe half the dose, i.e. half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet in the evening.

If you are being treated for chronic heart failure

The recommended initial dose is one 5 mg Ivabradina tablet twice daily, which may be increased if necessary to one 7.5 mg Ivabradina tablet twice daily. Your doctor will decide the appropriate dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g. if you are an elderly patient), your doctor may prescribe half the dose, i.e. half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet in the evening.

If you take more Ivabradina tablets than you should

An excessive dose of Ivabradina tablets may make you feel tired or short of breath due to your heart beating too slowly. If this happens, contact your doctor immediately.

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at 91 562 04 20, indicating the medicine and the amount ingested.

If you forget to take Ivabradina tablets

If you forget to take a dose of Ivabradina tablets, take the next dose at the scheduled time. Do not take a double dose to make up for forgotten doses.

The calendar printed on the blister pack containing the tablets will help you remember when you last took an Ivabradina tablet.

If you stop taking Ivabradina tablets

Treatment for stable angina or chronic heart failure is usually lifelong, so you must consult your doctor before stopping this medicine.

If you think that the effect of Ivabradina tablets is too strong or too weak, inform your doctor or pharmacist.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

The frequency of the possible adverse effects listed below is defined using the following system:

Very common: may affect more than 1 in 10 people.
Common: may affect up to 1 in 10 people.
Uncommon: may affect up to 1 in 100 people.
Rare: may affect up to 1 in 1,000 people.
Very rare: may affect up to 1 in 10,000 people.
Frequency not known: frequency cannot be estimated from the available data.

The most common adverse reactions with this medicine are dose-dependent and are related to its mechanism of action:

Very common:

Luminous visual phenomena (brief moments of increased brightness, usually caused by sudden changes in light intensity). These may also be described as halos, flashes of color, image fragmentation, or multiple images. These usually appear during the first two months of treatment and may recur repeatedly, resolving during or after treatment.

Common:

Changes in heart function (symptoms include slowing of the heart rate). This occurs especially during the first 2 to 3 months after starting treatment.

Other adverse effects that have been reported include:

Common:

Rapid irregular heartbeat, sensation of abnormal heartbeat, uncontrolled blood pressure, headache, dizziness, and blurred vision (cloudy vision).

Uncommon:

Palpitations and extra heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle cramps, changes in laboratory tests: elevated blood levels of uric acid, excess eosinophils (a type of white blood cell), and elevated blood creatinine levels (a muscle breakdown product), skin rash, angioedema (such as swelling of the face, tongue, or throat, difficulty breathing or swallowing), low blood pressure, fainting, feeling of fatigue, feeling of weakness, abnormal electrocardiogram, double vision, visual disturbance.

Rare:

Urticaria, itching, redness of the skin, malaise.

Very rare:

Irregular heartbeats.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if
such possible adverse effects are not listed in this leaflet. You may also
report them directly through the Spanish Pharmacovigilance System for
Human Medicines: https://www.notificaram.es. By reporting
adverse effects, you can help provide more information on the safety of
this medicine.

5. Storage of Ivabradine Kern Pharma tablets

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging, after EXP. The expiry date is the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at a SIGRE Point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Ivabradina Kern Pharma tablets

  • The active substance is ivabradine (as hydrochloride).

Each tablet contains 7.5 mg of ivabradine (equivalent to 8.085 mg of ivabradine hydrochloride).

  • The other components are: monohydrate lactose, pregelatinized corn starch, corn maltodextrin, anhydrous colloidal silica (E551), and magnesium stearate (E470b).

Appearance of the product and contents of the container

Ivabradina Kern Pharma 7.5 mg are white or almost white, round, biconvex tablets, smooth on both sides.

The tablets are presented in PA/Al/PVC-Aluminum blisters, calendared in packs of 56 tablets.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Kern Pharma, S.L.

Venus, 72 – Pol. Ind. Colón II

08228 Terrassa – Barcelona

Spain

Manufacturer:

Laboratorios Alter, S.A.

C/ Mateo Inurria 30

28036 Madrid

Spain

Date of the most recent review of this leaflet: October 2016.

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es.